AUTHORS
Sudipto Mukherjee, MD, PhD, MPH, Fatima Hussain, MPH2, Vu Long, MS3, Christopher Swetel, N/A4, Hetty Carraway, MD, MBA5, Akriti G Jain, MD, FACP6, Aaron T. Gerds, MD, MS7, John Carlos Molina, MD, MEd8, Deepa Jagadeesh, MD, MPH9, Johnie Rose, MD, PhD10, Jack Khouri, MD11, Brian Hill, MD, PhD12, Sophia Rebecca Balderman, MD13, Moaath Mustafa Ali, MD, MPH14, Anjali Sunder Advani, MD15, Abhay Singh, MD, MPH16, Faiz Anwer, MD17, Paolo Fabrizio Caimi, MD18, Siran M. Koroukian19
AFFILIATIONS
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Case Western Reserve University, Cleveland, Ohio, United States
3 Case Western Reserve University, Cleveland, Ohio, United States
4 Case Western Reserve University, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Case Western Reserve University, Cleveland, Ohio, United States
11 Cleveland Clinic, Cleveland, Ohio, United States
12 Cleveland Clinic, Cleveland, Ohio, United States
13 Cleveland Clinic, Cleveland, Ohio, United States
14 Cleveland Clinic, Cleveland, Ohio, United States
15 Cleveland Clinic, Cleveland, Ohio, United States
16 Cleveland Clinic, Cleveland, Ohio, United States
17 Cleveland Clinic, Cleveland, Ohio, United States
18 Cleveland Clinic, Cleveland, Ohio, United States
19 Case Western Reserve University, Cleveland, Ohio, United States
ABSTRACT
Introduction
Clinical trial participation (CTP) by older adults (³ 65 years) with hematologic malignancies has remained persistently low over the last several decades. Older adults who represent the majority of new diagnoses in leukemias, lymphomas, and myeloma—remain markedly under-represented in U.S. clinical trials. To help increase CTP in this patient (pt) population, we identified sociodemographic and clinical factors associated with CTP, using SEER-Medicare data.
Methods
We used SEER-Medicare data linked with data from ClinicalTrials.gov for patients diagnosed with hematologic malignancies during the years 2014-2021. The Centers for Medicare & Medicaid Services (CMS) has required that the National Clinical Trial (NCT) number be documented in claim records for individuals enrolled in trials since 2014. From the ClinicalTrials.gov, we identified NCTs for trials targeted to pts with hematologic cancers. From the SEER, we identified cancer type and grouped them in the following categories: lymphoid leukemia (ALL/CLL), myeloid leukemia (AML/CML), lymphomas (HL/NHL), MDS/MPN, and multiple myeloma. We also retrieved sociodemographic variables (age, sex, race/ethnicity, and); county of residence, using the Rural-Urban Continuum Codes; cancer type; and year of diagnosis. In addition to CTP, we used Medicare data to flag 67 chronic and potentially disabling conditions compiled by CMS, derive claims-based frailty indicator, and admission to nursing facilities, as an additional proxy for vulnerability to adverse health outcomes. In addition to detailed descriptive analysis, we relied on machine learning approaches (XGBoost and SHAP analysis) to rank variables by importance in predicting CTP, stratified by cancer type. Variables included age; sex; race/ethnicity; rural-urban continuum codes for patients’ county of residence; frailty; and comorbid conditions (e.g., hypertension, diabetes, and chronic kidney disease).
Results
Our study population included 169,514 pts with incident hematologic cancer and receiving their care through the fee-for-service system; the median age was 76 (IQR: 71-83); 55.9% were men; 83.1% were non-Hispanic White; 31.6% resided in Metro areas with population of fewer than 250,000 or non-Metro areas. One third of the study population were diagnosed with leukemias (ALL/CLL: 20.2%, and AML/CML: 13.1%); 43.5% were diagnosed with lymphomas; 3.6% were diagnosed with MDS/MPN; and 19.7% were diagnosed with multiple myeloma. The median number of comorbid conditions was 4 (IQR: 2-8), and 10.4% had been admitted to a nursing facility in the year prior to cancer diagnosis. Overall, 2.9% of pts participated in clinical trials and this rate remained stable with minor fluctuations over each of the years in the study period. CTP was highest in pts 66-74 years of age (4.6%), in pts with AML or CML (6.6%), and among those with MDS/MPN (5.9%). Conversely, CTP was 2.7%, 2.4%, and 1.4% in pts with multiple myeloma, lymphomas, and lymphoid leukemias, respectively. CTP was higher in men than in women (3.1% vs. 2.7%); higher in non-Hispanic Whites (3.1%) and non-Hispanic Asians (3.0%) than in non-Hispanic Blacks (2.0%) or Hispanics (2.5%); higher among non-frail pts (4.0%) than in pre-frail (2.8%) or frail pts (1.1%); higher in large Metro Counties (3.2%) than in smaller Metro or non-Metro counties (2.7% or lower); and higher in residents of Seattle, Massachusetts, or Texas (4.0-4.1%) than in other areas. Lastly, the mean number of comorbid conditions was 2.9 in people participating in trials and 3.68 in their non-participating counterparts. Results from the XGBoost and SHAP analysis showed that, consistently across all hematopoietic cancer types, age and frailty were the most important variables predicting CTP. Non-Hispanic Black race emerged among the top 5 most important variables predicting CTP only in pts with multiple myeloma.
Conclusions
Despite decades of therapeutic advances, fewer than 1 in 30 older adults with hematologic malignancies participate in clinical trials. Across hematologic cancer subtypes, advanced age and frailty are the strongest determinants of trial participation, while geographic and racial disparities further limit enrollment. These findings suggest that improving representation of older adults will require trial designs that address frailty and structural barriers rather than disease-specific eligibility alone.
DISCLOSURES
Sudipto Mukherjee, MD, PhD, MPH: Sobi - Consultancy (Includes expert testimony); Recordati - Consultancy (Includes expert testimony); CCM Biosciences - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); McGraw Hill - Consultancy (Includes expert testimony); Blueprint Medicines - Consultancy (Includes expert testimony)